| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_IGFBP2_0000100 | Exon-Exon | chr2:217498247-217529156 | chr2:216633524-216664433 | 1307 nt | 0.6641 |
| hsa_IGFBP2_0000100 | Exon-Exon | chr2:217498247-217529156 | chr2:216633524-216664433 | 1307 nt | 0.6641 |
| hsa_chr2_0528100 | Intergenic-Intergenic | chr2:217498191-217526673 | chr2:216633468-216661950 | 821 nt | 0.7308 |
| hsa_IGFBP2_0000200 | Exon-Exon | chr2:217498358-217525360 | chr2:216633635-216660637 | 412 nt | 0.7379 |
| hsa_chr2_0528200 | Intergenic-Intergenic | chr2:217498589-217526664 | chr2:216633866-216661941 | 414 nt | 0.6570 |
| hsa_IGFBP2_0000300 | Exon-Exon | chr2:217498613-217526721 | chr2:216633890-216661998 | 76 nt | 0.6974 |
| hsa_IGFBP2_0000400 | Exon-Exon | chr2:217498631-217525311 | chr2:216633908-216660588 | 90 nt | 0.6444 |
| hsa_chr2_0528300 | Intergenic-Intergenic | chr2:217512626-217516566 | chr2:216647903-216651843 | 250 nt | 0.3800 |
| hsa_IGFBP2_0000500 | Exon-Exon | chr2:217525280-217525509 | chr2:216660557-216660786 | 230 nt | 0.6304 |
| hsa_IGFBP2_0000600 | Exon-Exon | chr2:217525280-217526721 | chr2:216660557-216661998 | 371 nt | 0.6199 |
A study in humans demonstrated that circIGFBP2 is significantly increased in serum exosomes of patients with metastatic pancreatic cancer, where its levels correlate with TNM stages and poor prognosis [Misir et al. DOI:10.1038/s41418-022-00948-7].